T1	intervention 70 79	tamoxifen
T3	total-participants 568 572	2494
T4	control 620 627	placebo
T5	eligibility 573 586	healthy women
T6	outcome-Measure 665 701	occurrence of invasive breast cancer
T7	outcome-Measure 735 789	estrogen receptor (ER)-positive invasive breast cancer
T8	total-participants 1054 1058	2471
T9	intervention-participants 1082 1086	1238
T10	control-participants 1125 1129	1233
T11	outcome 1178 1200	invasive breast cancer
T12	iv-bin-abs 1202 1204	82
T13	cv-bin-abs 1222 1225	104
T14	outcome 1349 1360	ER positive
T15	iv-bin-abs 1362 1364	53
T16	cv-bin-abs 1382 1384	86
T17	outcome 1446 1479	risk of ER-positive breast cancer
T18	iv-bin-abs 1603 1605	30
T19	cv-bin-abs 1639 1641	39
T20	outcome 1753 1773	posttreatment period
T21	iv-bin-abs 1775 1777	23
T22	cv-bin-abs 1803 1805	47
T23	iv-bin-abs 1871 1881	Fifty-four
T25	outcome 1912 1916	died
T2	outcome 1981 2003	adverse event profiles
